Sareum is a specialist small molecule drug discovery and development company with programs in oncology and inflammatory disorders. Sareum is virtual, using collaborators and contract research organisations to progress its programs and then out-licensing them in return for up-front payments, future milestones and long-term sales royalties. Sareum, together with its partner CRT Pioneer Fund, has announced the exclusive licence and worldwide rights for its Chk1 pre-clinical cancer candidate CCT245737 (renamed PNT737) to ProNAi Therapeutics Inc, for $7m upfront, plus a total of $321.5m potential milestones, and sales royalties.
